FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia
- 12 November 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 84 (12), 792-795
- https://doi.org/10.1007/s00277-005-1090-9
Abstract
Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis. The strategy for treating these patients is through reinduction chemotherapy followed by allogeneic stem cell transplantation, provided that the toxicity of the salvage regimen is acceptable. Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA). Five patients had primary refractory disease, and 18 were in first relapse. Nine (39.1%) patients achieved complete remission (CR) following salvage therapy, whereas 13 (56.5%) patients were refractory, and one patient died in aplasia due to infection. In patients achieving remission, the median time to reach absolute neutrophil count (ANC) more than 0.5×109/l and 1×109/l was 20 (range 16–25) and 24 (range 20–28) days from the start of chemotherapy, respectively. Platelet levels of more than 20×109/l and 100×109/l were achieved in a median time of 23 (range 19–25) and 33 (range 28–39) days, respectively. Fever more than 38.5°C was observed in 18 of 23 patients (78.2%), 13 had fever of unknown origin, and 5 had documented infections. Nonhematological side effects, consisting mainly of mucositis (18/23 or 78.2%) and transient liver toxicity increase (10/23 or 43.4%), were generally tolerated. All nine patients who achieved CR received a second course with FLAG-IDA, and seven patients underwent allogeneic stem cell transplantation (four from a matched donor, one from a mismatched donor, and two from an unrelated donor), while two did not reach that stage due to early relapse from CR. The median overall survival (OS) for all 23 patients was 4.5 (range 1–38) months; for the nine responders, the disease-free survival (DFS) and the OS were 6 (range 3–38) and 9 (7–38) months, respectively; the seven patients who received allogeneic stem cell transplantation had a DFS of 10 (range 7–38) months. In our experience, FLAG-IDA is a well-tolerated regimen in relapsed/refractory ALL patients; the toxicity is acceptable, enabling patients who have achieved CR to receive allogeneic transplantation.This publication has 13 references indexed in Scilit:
- Outcome of relapsed or refractory childhood B‐cell acute lymphoblastic leukaemia and B‐cell non‐Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocolsBritish Journal of Haematology, 2001
- Primary refractory and relapsed adult acute lymphoblastic leukemiaCancer, 1999
- Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial TherapyBlood, 1998
- Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemiaBone Marrow Transplantation, 1998
- The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemiaLeukemia, 1997
- Treatment of Relapsed Adult Acute Lymphoblastic Leukemia with Fludarabine and Cytosine Arabinoside Followed by Granulocyte Colony-Stimulating Factor (FLAG-GCSF)Leukemia & Lymphoma, 1997
- Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP* experienceBritish Journal of Haematology, 1994
- Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemiaCancer, 1993
- Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.Journal of Clinical Oncology, 1993
- Treatment of relapsed or refractory adult acute lymphocytic leukemiaCancer, 1992